Summit Therapeutics is trading 4.65% lower at $14.75, with a likely company-specific overhang from October 25 HARMONi lung-cancer trial results: the reported 21% survival improvement did not meet statistical significance.
- Ivonescimab plus chemotherapy improved progression-free survival in HARMONi.
- Positive HARMONi-GI1 biliary-cancer results were announced around the same time, making the news mixed.
- Modest broad-market gains do not explain the decline; Q3 earnings expectations alone are not a reported earnings result.